Labcorp Holdings Inc. introduced the Labcorp Fentanyl Urine Visual Test, the first rapid fentanyl screening kit cleared by the U.S. Food and Drug Administration and manufactured domestically. The test delivers a visual result in 10 minutes by detecting norfentanyl, the primary fentanyl metabolite that can be found in urine for up to 48 hours after exposure.
The launch is part of Labcorp’s broader specialty‑testing expansion, which included more than 130 new tests in 2025. By adding a high‑margin, high‑velocity product, Labcorp aims to strengthen its role as an indispensable partner for health systems and to capture growth in high‑margin specialty areas such as oncology, women’s health, autoimmune disease, and neurology.
The need for rapid, reliable fentanyl screening is underscored by recent data: 4% of pre‑employment screenings and nearly 10% of patients in opioid‑use‑disorder treatment tested positive for fentanyl between 2024 and 2025. The Association for Diagnostics and Laboratory Medicine highlighted the growing demand for such tools, and the quick turnaround of the new test is designed to support clinicians in emergency departments, hospitals, and outpatient clinics.
Dr. Brian Caveney, Labcorp’s chief medical and scientific officer, noted that “When clinicians suspect fentanyl exposure, they need quick, dependable answers to inform care. The Labcorp Fentanyl Urine Visual Test delivers results in minutes, helping teams respond swiftly and confidently.” The product launch follows Labcorp’s Q4 2025 earnings, which showed a 7.2% revenue increase to $13.95 billion and a 13% rise in adjusted EPS, and aligns with the company’s 2026 guidance of 5.4% revenue growth and 8.9% EPS growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.